Clinical trial
An Open-label Phase II Study of the Efficacy and Safety of the Combination of Fludarabine, Cyclophosphamide and Rituximab in Patients With Chronic Lymphocytic Leukaemia Who Are Newly Diagnosed, Have Relapsed or Are Resistant to First-Line Treatment
NCT00812669 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Phase II Study of the Efficacy and Safety of the Combination of Fludarabine, Cyclophosphamide and Rituximab in Patients With Chronic Lymphocytic Leukaemia Who Are Newly Diagnosed, Have Relapsed or Are Resistant to First-Line Treatment
- Lead sponsor
- Cancer Trials Ireland
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 18, 2008
- Completion date
- November 21, 2019
- Enrollment
- 52 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.